Market Place
Sourcing Support
J&J seeks expanded approvals for paediatric HIV-1 therapy
05 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Fore Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394
12 Sep 2022 //
BUSINESSWIRE
J&J-backed AIDS film picked up by Verizon Media
10 May 2019 //
FIERCE PHARMA
Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen
11 Apr 2019 //
PR NEWSWIRE
Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma
29 Jan 2019 //
PATENT LITIGATION
NHS England agrees to fund Janssen’s Symtuza
02 Oct 2018 //
PHARMA TIMES
China National Drug Administration Approves Gilead`s Genvoya
06 Aug 2018 //
PRESS RELEASE
J&J joins blockbuster HIV combo race with newly approved 4-in-1 pill
19 Jul 2018 //
ENDPTS
Is Gilead Poised for a Comeback?
07 Jul 2018 //
BIOSPACE
Truvada® (emtricitabine & tenofovir disoproxil fumarate)elvitegravir, GS 9350 (cobicistat): ViiV Healthcare v. Gilead Sciences
07 Feb 2018 //
PATENT LITIGATION
Evotaz® (Atazanavir And Cobicistat): Gilead Sciences v. Mylan Pharmaceuticals
15 Dec 2017 //
PATENT LITIGATION
Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA
25 Oct 2017 //
BUSINESSWIRE
Janssen-Cilag International Generic Symtuza Receives Approval In Europe
27 Sep 2017 //
EMA
EC approves Janssen’s Symtuza
26 Sep 2017 //
PHARMA TIMES
FDA Accepts Supplemental NDA for Eisai`s Lenvatinib for Treatment Liver Cancer
26 Sep 2017 //
PR NEWSWIRE
Gilead’s genvoya shows significantly higher rates of virologic suppression
15 Feb 2017 //
PHARMABIZ
The Glaxo-Gilead HIV Battle Could Be Epic
28 Dec 2016 //
SEEKING ALPHA
Gilead asks FDA to Expand Exclusivity for a Key HIV Drug
21 Oct 2016 //
STAT
Gilead HIV biz draws farther ahead of ViiV with Descovy`s FDA nod: analyst
25 Apr 2016 //
FIERCE PHARMA MARKETING
Gilead gains next-gen HIV approval from FDA as it looks to beat back competition
06 Apr 2016 //
FIERCE BIOTECH
NHS England funds Janssen`s HIV pill Rezolsta
31 Mar 2016 //
PHARMATIMES
Gilead`s latest HIV cocktail wins FDA approval with a blockbuster pedigree
01 Mar 2016 //
FIERCE BIOTECH
Analyzing Data for Earliest Market Entry for Subsequent ANDA Filers
12 Feb 2016 //
TWOFOUR INSIGHT
Three Biotech Stocks You Don`t Have to Constantly Monitor
02 Feb 2016 //
BIOSPACE
EU clears single pill HIV therapy Genvoya
25 Nov 2015 //
PHARMATIMES
Gilead, Sanofi singled out as worst offenders in failing to disclose trial data
12 Nov 2015 //
FIERCE BIOTECH
FDA approves new treatment for HIV
06 Nov 2015 //
FDA
ViiV Healthcare Attacking, but Gilead Prepares to Strike Back
03 Nov 2015 //
MOTLEY FOOL
Janssen`s Prezcobix effort tap HIV activist to curate patient-story
22 Sep 2015 //
FIERCE PHARMA MARKETING
Gilead`s low-dose, high-impact HIV drug heads to the FDA
09 Apr 2015 //
SAN FRANSISCO BUSINESS TIMES
Janssen Therapeutics`s PREZCOBIX (Darunavir/Cobicistat) Approved in USA for HIV-1
31 Jan 2015 //
JANSSEN THERAPEUTICS
Janssen`s PREZCOBIX (Darunavir/Cobicistat) Approved in USA for HIV-1
29 Jan 2015 //
JANSSEN
Johnson & Johnson’s Rezolsta Approved in the EU for HIV-1
12 Dec 2014 //
